OTCMKTS:LBTSF Almirall 7/24/2026 Earnings Report $15.35 0.00 (0.00%) As of 06/30/2026 ProfileForecast Almirall EPS ResultsActual EPSN/AConsensus EPS $0.10Beat/MissN/AOne Year Ago EPSN/AAlmirall Revenue ResultsActual RevenueN/AExpected Revenue$353.67 millionBeat/MissN/AYoY Revenue GrowthN/AAlmirall Announcement DetailsQuarterDate7/24/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Almirall Earnings HeadlinesAlmirall S.A.April 20, 2026 | marketwatch.comSpain's Almirall in talks with 'dozens' of firms to license China assets, CEO saysMarch 12, 2026 | msn.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.July 2 at 1:00 AM | Stansberry Research (Ad)Almirall SA (LBTSF) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic InvestmentsFebruary 23, 2026 | uk.finance.yahoo.comAlmirall, S.A.: Almirall's 2025 ResultsFebruary 23, 2026 | finanznachrichten.deEpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner AlmirallFebruary 10, 2026 | markets.businessinsider.comSee More Almirall Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Almirall? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Almirall and other key companies, straight to your email. Email Address About AlmirallAlmirall (OTCMKTS:LBTSF) is a research-driven pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943, the firm has evolved into a specialist in dermatology, dedicating its efforts to understanding and treating a range of inflammatory and chronic skin conditions. Over the decades, Almirall has built a reputation for its targeted R&D approach and its commitment to improving patient outcomes in dermatological care. The company’s core activities span the research, development, manufacturing and marketing of prescription therapies for skin diseases. Its marketed portfolio includes products such as Actikerall, a topical treatment for actinic keratosis; Solaraze, a diclofenac-based gel for actinic keratosis and superficial basal cell carcinoma; and Skilarence (apremilast), an oral therapy for plaque psoriasis. Almirall’s pipeline features investigational small molecules and biologics aimed at conditions like eczema, hidradenitis suppurativa and other inflammatory dermatoses. Almirall operates across Europe, North America and Latin America, leveraging a network of subsidiaries, local partnerships and strategic alliances to distribute its products. The company maintains research centres in Barcelona and other European locations, collaborating with academic institutions and biotech firms to accelerate innovation. Looking ahead, Almirall continues to pursue growth in its core dermatology franchise while exploring adjacent opportunities through licensing deals and co-development agreements.View Almirall ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases3 Charts That Could Change the Course of Summer TradingWhy Wall Street Still Sees Massive Upside for AeroVironment StockManchester United’s Stock Rally Faces a Test Beyond Old Trafford Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
